Clinical Trials Browser

Phase 2 × Neoplasm, Residual × 1 year × Clear all

NCT03876769 2026-06-02

CASSIOPEIA

Phase 2 Active not recruiting

Burkitt Lymphoma, Neoplasm, Residual

NCT06500273 2026-06-02

ALPHA3

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07136077 2026-06-01

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT06993675 2026-05-13

ROTATE

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

NCT07517705 2026-05-13

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07572929 2026-05-07

PREeMPT

Phase 2 Not yet recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04434040 2026-05-04

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT03863184 2026-04-28

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Phase 2 Active not recruiting

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT07069595 2026-04-22

PREDICT-RD

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04841148 2026-04-09

PALAVY

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT07392970 2026-04-09

Motixafortide for MRD Sensitization in AML

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2 Recruiting

CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT03516279 2026-04-03

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT07507318 2026-04-02

DEL-MRD-CHID

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT05690984 2026-03-16

EMAT

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasm, Residual

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT05708235 2026-03-05

MiRaDoR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT05429320 2026-02-02

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT02389517 2026-01-22

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Phase 2 Completed

42 enrolled 11 charts

Multiple Myeloma, Neoplasm, Residual

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Phase 2 Recruiting

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07257380 2025-12-02

MRD-ATLAS

Phase 2 Not yet recruiting

Neoplasm, Residual

NCT02666898 2025-11-26

ICLL07GAI

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT06828991 2025-10-20

GOLD

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT02458014 2025-09-23

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

Phase 2 Completed

Burkitt Lymphoma, Neoplasm, Residual

NCT06668558 2025-09-19

VERDI

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Phase 2 Active not recruiting

175 enrolled 16 charts

Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

NCT04827745 2025-07-03

Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Neoplasm, Residual

NCT07021677 2025-06-15

DARA_T_ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma